Sign inJoin waitlistJoin the waitlist

Rachna Shroff

Associate Director, Clinical Investigations, Cancer Center · University of Arizona College of Medicine-Tucson

Credentials: · · · · ·

History

Division of Hematology/Oncology · University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine-Tucson
Present

Baylor College of Medicine
2012
Medical Oncology
University of Texas Health Science Center at Houston
2007–2010
Internal Medicine
University of Washington-Seattle Campus
2004–2007
School of Biomedical Sciences, Houston
Sidney Kimmel Medical College at Thomas Jefferson University
2000–2004
Brown University
2000

Research

Pancreatic cancer
Review · The Lancet · 2020 · Last of 4 authors · Corresponding · 2,145 citations
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology · 2020 · 904 citations
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Journal of Clinical Oncology · 2018 · 536 citations

Milind Javle
50 papers
Robert Wolff
29 papers
GV
Gauri Varadhachary
23 papers
DF
David Fogelman
19 papers
Michael Overman
19 papers
Kate Kelley
16 papers
Lipika Goyal
13 papers
Matthew Katz
13 papers
Huamin Wang
12 papers
Mitesh Borad
12 papers
Ahmed Kaseb
11 papers
Christopher Crane
11 papers

Grants

Establishing the University of Arizona Cancer Center as a Lead Academic Participating Site in the National Clinical Trials Network
National Cancer Institute · UG1
Contact PI · $435.4K · University of Arizona
2026–2032
University of Arizona Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.8M · University of Arizona
1997–2027
Enhancing NCI-Funded Research at the University of Arizona Cancer Center
National Cancer Institute · R50
Contact PI · $575.1K · University of Arizona
2025–2026
DNA Methylation, Liquid Biopsy, and Pancreatic Cancer
National Cancer Institute · R21
PI · $215.3K · University of Arizona
2022–2024

Clinical trials

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Principal investigator · Active not recruiting · Phase 2
University of Arizona
2021–2027
Immune Response to the COVID-19 Vaccine
Principal investigator · Completed · Early phase 1
University of Arizona
2021–2022
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
Principal investigator · Completed · Phase 3
SWOG Cancer Research Network
2019–2024
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2015–2022